Esperion Therapeutics (ESPR) Net Margin (2019 - 2026)

Esperion Therapeutics has reported Net Margin for 8 years, with the latest figure at 32.93% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin rose 3096.0% year-over-year to 32.93%; the trailing twelve-month figure through Mar 2026 stood at 2.2% (up 4128.0% YoY), and the FY2025 full-year result was 5.63%, up 994.0% from the prior year.
• Net Margin for Q1 2026 stood at 32.93%, down from 37.16% in the prior quarter.
• The five-year high for Net Margin was 42.29% in Q1 2024, with the low at 353.71% in Q2 2022.
• Historically, Net Margin has averaged 129.56% across 5 years, with a median of 63.89% in 2025.
• The largest YoY upside for Net Margin was 83711 bps in 2022 against a maximum downside of 24628 bps in 2022.
• Esperion Therapeutics' Net Margin stood at 302.06% in 2022, then jumped by 41 bps to 178.06% in 2023, then jumped by 76 bps to 42.07% in 2024, then jumped by 188 bps to 37.16% in 2025, then sank by 189 bps to 32.93% in 2026.
• The last three Net Margin figures came in at 32.93% (Q1 2026), 37.16% (Q4 2025), and 36.66% (Q3 2025), per Business Quant data.